2010 Fiscal Year Final Research Report
Mechanism of drug resistance among HBV genotypes
| Project/Area Number |
20390213
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
MIZOKAMI Masashi Nagoya City University, 大学院・医学研究科, 客員教授 (40166038)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Yasuhito 名古屋市立大学, 大学院・医学研究科, 教授 (90336694)
SUGAUCHI Fuminaka 名古屋市立大学, 大学院・医学研究科, 研究員 (20405161)
FUAT Kurbanov 名古屋市立大学, 大学院・医学研究科, 特任助教 (10444978)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | B型肝炎ウイルス / エンテカビル / ラミブジン / 薬剤耐性 / キメラマウス |
|---|
| Research Abstract |
1. Randomized controlled trial evidenced that switching treatment to ETV was recommended during at least 2 years' follow-up period in patients treated with LAM for more than 3 years maintaining HBV DNA less than 2.6 log copies/m. 2. Using chimeric mice model, we found new small compounds to inhibit ETV resistant. 3. We found that the low binding affinity for ETV to the DNA binding domains, involving conformationalchange of the binding pocket of HBV RT by the ETVr substitutions, could induce BT. ETV should be considered as a first-line option for nucleoside-naive patients ; however, it is not an optimal therapy for patients with LVDr.
|
